Journal of Cardiothoracic and Vascular Anesthesia
Volume 23, Issue 5 , Pages 619-624, October 2009

Morphine Reduces the Threshold of Helium Preconditioning Against Myocardial Infarction: The Role of Opioid Receptors in Rabbits

Preliminary data in this article were presented in abstract form (Anesthesiology 109:A298, 2008) at the annual meeting of the American Society of Anesthesiologists, Orlando, FL, October 18-22, 2008.

Department of Anesthesiology, Medical College of Wisconsin and Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI

published online 23 February 2009.

Objectives

Brief, repetitive administration of helium before prolonged coronary artery occlusion and reperfusion protects myocardium against infarction. Opioid receptors mediate the cardioprotective effects of ischemic pre- and postconditioning, but whether these receptors also play a role in helium preconditioning is unknown. The authors tested the hypotheses that opioid receptors mediate helium preconditioning and that morphine (a μ1-opioid receptor agonist with δ1-opioid agonist properties) lowers the threshold of cardioprotection produced by helium in vivo.

Design

A randomized, prospective study.

Setting

A university research laboratory.

Participants

Male New Zealand white rabbits.

Interventions

Rabbits (n = 56) were instrumented for the measurement of systemic hemodynamics and subjected to a 30-minute left anterior descending coronary artery (LAD) occlusion and 3 hours of reperfusion. In separate experimental groups, rabbits (n = 6 or 7 per group) received 0.9% saline (control), 1 or 3 cycles of 70% helium–30% oxygen administered for 5 minutes interspersed with 5 minutes of an air-oxygen mixture, morphine (0.1 mg/kg intravenously), or the nonselective opioid antagonist naloxone (6 mg/kg intravenously) before LAD occlusion. Other groups of rabbits received 3 cycles of helium or 1 cycle of helium plus morphine (0.1 mg/kg) in the absence or presence of naloxone (6 mg/kg) before ischemia and reperfusion. Statistical analysis of data was performed with analysis of variance for repeated measures followed by Bonferroni modification of the Student t test.

Measurements and Main Results

Myocardial infarct size was determined by using triphenyltetrazolium chloride staining and presented as a percentage of the left ventricular area at risk. Helium reduced myocardial infarct size in an exposure-related manner (36 ± 6 [p > 0.05] and 25% ± 4% [p < 0.05 v control] for 1 and 3 cycles of helium, respectively; data are mean ± standard deviation) compared with control (44% ± 7%). Morphine and naloxone alone did not affect infarct size (45 ± 2 and 40% ± 8%, respectively). The combination of 1 cycle of helium and morphine reduced infarct size (24% ± 5%, p < 0.05 v control) to an equivalent degree as 3 cycles of helium. Naloxone pretreatment abolished cardioprotection produced by 3 cycles of helium (47% ± 2%) and the combination of 1 cycle of helium plus morphine (45% ± 4%).

Conclusions

The results indicate that morphine lowers the threshold of helium preconditioning. Opioid receptors mediate helium preconditioning and its augmentation by morphine in vivo.

Key Words: myocardial ischemia, preconditioning, helium, morphine, opioid receptor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by National Institutes of Health grants HL 054820 and GM 066730 from the United States Public Health Service (Bethesda, MD) and by departmental funds. J.A. is the recipient of research fellowship grants from the Société Française d'Anesthésie et de Réanimation (SFAR, Paris, France), Novo Nordisk (Paris-La Défense, France), and the Assistance Publique des Hôpitaux de Paris (APHP, Paris, France).

PII: S1053-0770(08)00385-6

doi:10.1053/j.jvca.2008.12.020

Journal of Cardiothoracic and Vascular Anesthesia
Volume 23, Issue 5 , Pages 619-624, October 2009